Curated News
By: NewsRamp Editorial Staff
June 03, 2025
Cure Alzheimer’s Fund Strengthens Board with Two New Appointments
TLDR
- Cure Alzheimer’s Fund strengthens its leadership with Christine Villas-Boas and Brittany Bowlen, enhancing strategic philanthropy to accelerate groundbreaking Alzheimer’s research.
- Cure Alzheimer’s Fund appoints Christine Villas-Boas and Brittany Bowlen to its Board, leveraging their expertise in strategy and philanthropy to advance Alzheimer’s research funding.
- Adding Christine Villas-Boas and Brittany Bowlen to Cure Alzheimer’s Fund’s Board amplifies efforts to combat Alzheimer’s, promising a brighter future for affected families worldwide.
- Christine Villas-Boas and Brittany Bowlen join Cure Alzheimer’s Fund’s Board, bringing fresh energy and diverse experience to the fight against Alzheimer’s disease.
Impact - Why it Matters
The appointment of Christine Villas-Boas and Brittany Bowlen to the Cure Alzheimer’s Fund Board of Directors signifies a bolstering of leadership and expertise in the fight against Alzheimer’s disease. With Alzheimer’s affecting an increasing number of individuals and families globally, the fund's dedication to funding critical research is more important than ever. The new board members' diverse backgrounds and commitment to philanthropy will enhance the organization's efforts to find a cure, offering hope to millions affected by this devastating disease. Their leadership is a testament to the fund's commitment to transparency and efficiency, ensuring that every dollar donated goes directly towards research that could one day prevent, slow, or reverse Alzheimer’s.
Summary
Cure Alzheimer’s Fund, a leading nonprofit in the fight against Alzheimer’s disease, has announced the appointment of Christine Villas-Boas and Brittany Bowlen to its Board of Directors. Both bring a wealth of experience and a deep commitment to the cause, with Villas-Boas serving as President and Treasurer of the Michel and Claire Gudefin Family Foundation, a major supporter of the fund, and Bowlen bringing her expertise from her role as Senior Vice President of Strategy for the Denver Broncos and her involvement in community impact initiatives. Their addition to the board is seen as a significant step forward in the organization's mission to fund groundbreaking research aimed at curing Alzheimer’s disease.
The organization, which has been instrumental in advancing Alzheimer’s research since its inception in 2004, has funded over 300 researchers with more than $232 million in grants, leading to key breakthroughs in understanding the disease. With a 100% perfect score from Charity Navigator for 13 consecutive years and a Platinum Seal of Transparency from Candid, Cure Alzheimer’s Fund ensures that 100% of general donations go directly to research, thanks to its board and trustees covering overhead expenses. This news highlights the fund's ongoing commitment to making a lasting impact in the fight against Alzheimer’s, a disease that affects millions worldwide.
Source Statement
This curated news summary relied on content disributed by News Direct. Read the original source here, Cure Alzheimer’s Fund Strengthens Board with Two New Appointments
